RT Journal Article
SR Electronic
T1 A catalog of associations between rare coding variants and COVID-19 outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.28.20221804
DO 10.1101/2020.10.28.20221804
A1 J. A. Kosmicki
A1 J. E. Horowitz
A1 N. Banerjee
A1 R. Lanche
A1 A. Marcketta
A1 E. Maxwell
A1 X. Bai
A1 D. Sun
A1 J. D. Backman
A1 D. Sharma
A1 H. M. Kang
A1 C. O’Dushlaine
A1 A. Yadav
A1 A. J. Mansfield
A1 A. H. Li
A1 K. Watanabe
A1 L. Gurski
A1 S. E. McCarthy
A1 A. E. Locke
A1 S. Khalid
A1 S. O’Keeffe
A1 J. Mbatchou
A1 O. Chazara
A1 Y. Huang
A1 E. Kvikstad
A1 A. O’Neill
A1 P. Nioi
A1 M. M. Parker
A1 S. Petrovski
A1 H. Runz
A1 J. D. Szustakowski
A1 Q. Wang
A1 E. Wong
A1 A. Cordova-Palomera
A1 E. N. Smith
A1 S. Szalma
A1 X. Zheng
A1 S. Esmaeeli
A1 J. W. Davis
A1 Y-P. Lai
A1 X. Chen
A1 A. E. Justice
A1 J. B. Leader
A1 T. Mirshahi
A1 D. J. Carey
A1 A. Verma
A1 G. Sirugo
A1 M. D. Ritchie
A1 D. J. Rader
A1 G. Povysil
A1 D. B. Goldstein
A1 K. Kiryluk
A1 E. Pairo-Castineira
A1 K. Rawlik
A1 D. Pasko
A1 S. Walker
A1 A. Meynert
A1 A. Kousathanas
A1 L. Moutsianas
A1 A. Tenesa
A1 M. Caulfield
A1 R. Scott
A1 J. F. Wilson
A1 J. K. Baillie
A1 G. Butler-Laporte
A1 T. Nakanishi
A1 M. Lathrop
A1 J.B. Richards
A1 Regeneron Genetics Center
A1 UKB Exome Sequencing Consortium
A1 M. Jones
A1 S. Balasubramanian
A1 W. Salerno
A1 A. R. Shuldiner
A1 J. Marchini
A1 J. D. Overton
A1 L. Habegger
A1 M. N. Cantor
A1 J. G. Reid
A1 A. Baras
A1 G. R. Abecasis
A1 M. A. Ferreira
YR 2021
UL http://medrxiv.org/content/early/2021/02/27/2020.10.28.20221804.abstract
AB Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease-19 (COVID-19), a respiratory illness that can result in hospitalization or death. We investigated associations between rare genetic variants and seven COVID-19 outcomes in 543,213 individuals, including 8,248 with COVID-19. After accounting for multiple testing, we did not identify any clear associations with rare variants either exome-wide or when specifically focusing on (i) 14 interferon pathway genes in which rare deleterious variants have been reported in severe COVID-19 patients; (ii) 167 genes located in COVID-19 GWAS risk loci; or (iii) 32 additional genes of immunologic relevance and/or therapeutic potential. Our analyses indicate there are no significant associations with rare protein-coding variants with detectable effect sizes at our current sample sizes. Analyses will be updated as additional data become available, with results publicly browsable at https://rgc-covid19.regeneron.com.Competing Interest StatementJ.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., D.S., F.S.P.K., J.D.B., C.O'D., A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, H.M.K., L.D., E.S., M.J., S.B., K.S.M, W.J.S., A.R.S., A.E.L., J.M., J.O., L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. X.Z., S.E., J.W.D. are employees of AbbVie and may hold stock in AbbVie. Financial support for this research was provided by AbbVie through the UKB Exome Sequencing Consortium. AbbVie participated in the interpretation of data, review, and approval of the publication. P.N. and M.M.P employees and stockholders of Alnylam Pharmaceuticals. J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital and these agencies had no role in the design, implementation or interpretation of this study. S.S., E.W., A.C.P., and E.N.S. are employed by Takeda. S.S. holds shares in Takeda and Janssen. The other authors declare no competing interests.Funding StatementThe Penn Medicine BioBank is funded by a gift from the Smilow family, the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA Award Number UL1TR001878, and the Perelman School of Medicine at the University of Pennsylvania. Whole genome sequencing of the Biobanque Québec Covid-19 cohort was funded by the CanCOGeN HostSeq project. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK and the Fonds de Recherche Québec Santé (FRQS). G.B.L. is supported by a joint research fellowship from Quebec's ministry of health and social services, and the FRQS. T.N. is supported by Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists and JSPS Overseas Challenge Program for Young Researchers. J.B.R. is supported by a FRQS Clinical Research Scholarship. The Columbia University Biobank was supported by Columbia University and the National Center for Advancing Translational Sciences, NIH, through Grant Number UL1TR001873. GenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome-Beit Prize award to J. K. Baillie (Wellcome Trust 103258/Z/13/A), a BBSRC Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and BBS/E/D/30002275), the Medical Research Council [grant MC_PC_19059]. Research performed at the Human Genetics Unit was funded by the MRC (MC_UU_00007/10, MC_UU_00007/15). Whole-genome sequencing was done in partnership with Genomics England and was funded by UK Department of Health and Social Care, UKRI and LifeArc. Genomics England and the 100,000 Genomes Project was funded by the National Institute for Health Research, the Wellcome Trust, the Medical Research Council, Cancer Research UK, the Department of Health and Social Care and NHS England. M Caulfield is an NIHR Senior Investigator. This work is part of the portfolio of translational research at the NIHR Biomedical Research Centre at Barts and Cambridge. LK was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). We acknowledge support from the MRC Human Genetics Unit programme grant, "Quantitative traits in health and disease" (U. MC_UU_00007/10). A. Tenesa acknowledges funding from MRC research grant MR/P015514/1, and HDR-UK award HDR-9004 and HDR-9003. Recruitment to GenOMICC was enabled by the National Institute of Healthcare Research Clinical Research Network (NIHR CRN) and the Chief Scientist Office (Scotland), who facilitate recruitment into research studies in NHS hospitals, and to the global ISARIC and InFACT consortia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank obtained ethical approval for this study by the North West Multicenter Research Ethics Committee and all participants gave written informed consent to participate and be followed up. The recruitment and sequencing of Columbia University COVID-19 Biobank participants were approved by the Columbia University IRB, protocol number AAAS7370; genetic analyses were approved by the Columbia University IRB, under protocol number AAAS7948. The BQC-19 received ethical approval for its activities from its multi-centric Centre Hospitalier de l'Université de Montréal ethics board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAssociation results reported in this manuscript are publicly available at https://rgc-covid19.regeneron.com https://rgc-covid19.regeneron.com